Physician Perceptions and Prescribing Patterns of Once-weekly Trelagliptin in the Management of Type 2 Diabetes Mellitus: A Cross-sectional Questionnaire-based Survey Across India

Background: Type 2 diabetes mellitus (T2DM) is a chronic, progressive metabolic disorder with increasing prevalence in India, imposing significant morbidity and healthcare burden. Dipeptidyl peptidase-4 inhibitors (DPP-4i) are established glucose-lowering agents, and Trelagliptin, a novel once-weekly DPP-4i, offers potential advantages in adherence and convenience. However, real-world evidence on its use in routine clinical practice remains scarce. Objectives: To evaluate physician perceptions, prescribing patterns, and clinical experience with Trelagliptin in the management of T2DM in India. Methods: A multicentre, questionnaire-based survey was conducted among 71 practicing medical professionals across diverse domains in India. The structured questionnaire captured respondents’ demographics, patient load and perceptions of glycaemic control, adherence, tolerability, safety, cost-effectiveness, and factors influencing Trelagliptin prescription. Descriptive statistics were used to analyse responses. Results: The results demonstrated that most of the respondents were consultant physicians (64.79%), followed by diabetologists/endocrinologists (18.31%) and other specialities (16.90%). Most respondents (70.42%) identified patients with poor adherence to daily medication as suitable candidates for Trelagliptin. Physicians perceived improved glycaemic control and adherence with Trelagliptin, as rated by 90.14% and 94.37% of respondents, respectively. Additionally, 32.39% of respondents perceived Trelagliptin as superior for glycaemic control, while 70.42% perceived higher adherence and 66.20% perceived greater cost-effectiveness compared with other DPP-4i. A majority of respondents (64.79%) emphasised the importance of reducing pill burden. Improved tolerability was rated by 97.18% of respondents. Conclusion: Based on physician perceptions, once-weekly Trelagliptin was considered a safe, effective, and convenient therapeutic option for T2DM, with respondents reporting perceived improvements in adherence and patient-centred care in routine clinical practice.